Free tool
FAERS Monitor: Gallium Ga 68 Gozetotide
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 212642 or its brand name (Gallium Ga 68 Gozetotide, Gallium Ga-68 Gozetotide). Reports on generic versions are filed under their own applications.
Reports
204
Serious
144
71% of reports
Hospitalization
65
Death reported
20
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hot flush36
- erectile dysfunction27
- fatigue15
- death11
- overdose9
- pathological fracture9
- aspartate aminotransferase increased8
- asthenia8
- rash8
- cerebral amyloid angiopathy7
- drug interaction7
- muscular weakness7
- alanine aminotransferase increased6
- hyperhidrosis6
- hypothyroidism6
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2022 | 10 |
| 2023 | 6 |
| 2024 | 7 |
| 2025 | 129 |
| 2026 | 52 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,955 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| cerebral amyloid angiopathySignal | 7 | 2236.7 | 1071.3 | 13,201 |
| pathological fractureSignal | 9 | 183.2 | 96.6 | 1,451 |
| erectile dysfunctionSignal | 27 | 108.5 | 76.4 | 2,771 |
| hot flushSignal | 36 | 49.3 | 36.6 | 1,660 |
| hypothyroidismSignal | 6 | 19.4 | 8.8 | 87 |
| aspartate aminotransferase increasedSignal | 8 | 15.5 | 7.9 | 95 |
| alanine aminotransferase increasedSignal | 6 | 10.1 | 4.6 | 41 |
| muscular weaknessSignal | 7 | 6.4 | 3.1 | 27 |
| hyperhidrosisSignal | 6 | 4.8 | 2.2 | 15 |
| drug interactionSignal | 7 | 4.5 | 2.2 | 16 |
| overdoseSignal | 9 | 4.3 | 2.3 | 20 |
| astheniaSignal | 8 | 2.2 | 1.1 | 4 |
| fatigue | 15 | 2.0 | 1.2 | 7 |
| rash | 8 | 1.9 | 1.0 | 3 |
| death | 11 | 1.3 | 0.7 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.